4//SEC Filing
Martin Tami Tillotson 4
Accession 0001104659-23-097813
CIK 0001356576other
Filed
Aug 31, 8:00 PM ET
Accepted
Sep 1, 5:00 PM ET
Size
9.0 KB
Accession
0001104659-23-097813
Insider Transaction Report
Form 4
Martin Tami Tillotson
VP of Regulatory Affairs
Transactions
- Exercise/Conversion
Common Stock
2023-08-30$23.99/sh+8,100$194,319→ 93,349 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2023-08-30−8,100→ 13,900 totalExercise: $23.99Exp: 2030-02-21→ Common Stock (8,100 underlying) - Sale
Common Stock
2023-08-30$32.00/sh−8,100$259,200→ 85,249 total
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.01, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F2]The option vests in four equal annual installments beginning on February 21, 2021.
Documents
Issuer
SUPERNUS PHARMACEUTICALS, INC.
CIK 0001356576
Entity typeother
Related Parties
1- filerCIK 0001539494
Filing Metadata
- Form type
- 4
- Filed
- Aug 31, 8:00 PM ET
- Accepted
- Sep 1, 5:00 PM ET
- Size
- 9.0 KB